Tiotropium (Spiriva®)

DRUG3 trials

Sponsors

Boehringer Ingelheim, University of Saskatchewan

Conditions

Asthma BronchialePulmonary Disease, Chronic Obstructive

Phase 3

Spiriva® Assessment of FEV1 (SAFE)

CompletedNCT00277264

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2002-01-31End: 2004-05-31Target: 914Updated: 2013-11-06

Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

TerminatedNCT00662740

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 2008-04-15End: 2008-11-21Updated: 2023-08-23

Phase 4

Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response

Not yet recruitingNCT06679465

University of SaskatchewanAsthma Bronchiale

Start: 2025-01-01End: 2027-01-31Target: 10Updated: 2024-11-07